CN110431228B - 合成嵌合痘病毒 - Google Patents

合成嵌合痘病毒 Download PDF

Info

Publication number
CN110431228B
CN110431228B CN201780078546.0A CN201780078546A CN110431228B CN 110431228 B CN110431228 B CN 110431228B CN 201780078546 A CN201780078546 A CN 201780078546A CN 110431228 B CN110431228 B CN 110431228B
Authority
CN
China
Prior art keywords
virus
scopv
vacv
schpxv
poxvirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780078546.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN110431228A (zh
Inventor
戴维·埃文斯
瑞安·诺伊斯
塞思·莱德曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN110431228A publication Critical patent/CN110431228A/zh
Application granted granted Critical
Publication of CN110431228B publication Critical patent/CN110431228B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201780078546.0A 2016-11-02 2017-11-02 合成嵌合痘病毒 Active CN110431228B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662416577P 2016-11-02 2016-11-02
US62/416,577 2016-11-02
US201662434794P 2016-12-15 2016-12-15
US62/434,794 2016-12-15
PCT/US2017/059782 WO2018085582A1 (en) 2016-11-02 2017-11-02 Synthetic chimeric poxviruses

Publications (2)

Publication Number Publication Date
CN110431228A CN110431228A (zh) 2019-11-08
CN110431228B true CN110431228B (zh) 2024-04-02

Family

ID=62075555

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780078546.0A Active CN110431228B (zh) 2016-11-02 2017-11-02 合成嵌合痘病毒

Country Status (14)

Country Link
US (2) US11345896B2 (enExample)
EP (1) EP3535389A4 (enExample)
JP (3) JP2019535311A (enExample)
CN (1) CN110431228B (enExample)
AU (2) AU2017353868C1 (enExample)
BR (1) BR112019008781A2 (enExample)
CA (1) CA3042694A1 (enExample)
IL (2) IL266399B2 (enExample)
MX (1) MX2019005102A (enExample)
NZ (1) NZ752893A (enExample)
SG (1) SG11201903893PA (enExample)
TW (2) TWI887191B (enExample)
WO (1) WO2018085582A1 (enExample)
ZA (3) ZA201902868B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112543806B (zh) * 2018-05-02 2025-06-06 戴维·埃文斯 合成嵌合痘苗病毒

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018085582A1 (en) 2016-11-02 2018-05-11 David Evans Synthetic chimeric poxviruses
WO2018148710A1 (en) * 2017-02-13 2018-08-16 Excision Biotherapeutics, Inc. Visualizing viral reservoirs and dissemination in vivo
US20240024393A1 (en) * 2019-01-25 2024-01-25 Virocure, Inc. Pharmaceutical composition for preventing or treating cancer, comprising squirrel fibroma virus and reovirus
US20230097513A1 (en) * 2020-02-03 2023-03-30 City Of Hope Poxvirus-based vectors produced by natural or synthetic dna and uses thereof
AU2021226592A1 (en) * 2020-02-26 2022-09-22 The Governors Of The University Of Alberta Recombinant poxvirus based vaccine against SARS-CoV-2 virus
EP4288076A4 (en) 2021-02-02 2025-01-22 Geovax, Inc. VIRAL CONSTRUCTS FOR USE IN ENHANCING T CELL PRIMING DURING VACCINATION
WO2023168286A1 (en) 2022-03-01 2023-09-07 Tonix Pharmaceuticals Holding Corp. Recombinant poxvirus based vaccine against the omicron strain of sars-cov-2 virus and variants thereof
CN117264909B (zh) * 2023-10-25 2024-11-26 深圳湾实验室 反式互补缺陷猴痘病毒及其应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2787577A (en) 1953-12-01 1957-04-02 Lilly Co Eli Stable smallpox vaccine
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US6723325B1 (en) 2001-04-23 2004-04-20 Acambis, Inc. Smallpox vaccine
US20040014034A1 (en) * 2002-06-06 2004-01-22 Evans David H Method of producing a recombinant virus
EP1678292A4 (en) 2003-09-18 2008-05-07 Univ Emory IMPROVED MVA VACCINES
JPWO2006022215A1 (ja) 2004-08-23 2008-05-08 財団法人ヒューマンサイエンス振興財団 ＳＡＲＳ−コロナウイルスタンパク質をコードするＤＮＡを保有する組換えワクチニアウイルスＤＩｓ株、およびその利用
CN101020055B (zh) 2006-02-16 2012-08-08 中国疾病预防控制中心性病艾滋病预防控制中心 基于复制型痘苗病毒载体的sars疫苗
WO2008100292A2 (en) 2006-10-16 2008-08-21 Genelux Corporation Modified vaccinia virus strains for use in diagnostic and therapeutic methods
WO2009117030A2 (en) * 2007-12-19 2009-09-24 Macrogenics, Inc. Improved compositions for the prevention and treatment of smallpox
FI20115914A7 (fi) 2011-09-16 2013-03-17 Oncos Therapeutics Ltd Muunnettu onkolyyttinen virus
WO2014160475A1 (en) 2013-03-13 2014-10-02 Aboody Karen S Tropic cell based virotherapy for the treatment of cancer
CA2909225C (en) 2013-04-10 2019-06-18 Tot Shanghai R&D Center Co., Ltd. Mutant vaccinia virus strains, uses thereof and method of producing the same
EP3045181B1 (en) 2015-01-19 2018-11-14 Ludwig-Maximilians-Universität München A novel vaccine against the middle east respiratory syndrome coronavirus (MERS-CoV)
HK1248588A1 (zh) 2015-08-11 2018-10-19 Calidi Biotherapeutics, Inc. 用於癌症治疗中的天花疫苗
AU2017332367B2 (en) 2016-09-21 2021-12-23 Stephen H. Thorne High mobility group box i mutant
WO2018085582A1 (en) 2016-11-02 2018-05-11 David Evans Synthetic chimeric poxviruses
ES2702618B2 (es) 2017-09-04 2019-10-31 Inst De Salud Carlos Iii Producto de combinación que comprende una célula madre mesenquimatosa modificada y una sustancia antigénica.
CA3098145A1 (en) 2018-05-02 2019-11-07 Tonix Pharma Holdings Limited Stem cells comprising synthetic chimeric vaccinia virus and methods of using them
MX2020011586A (es) 2018-05-02 2020-12-07 David Evans Virus vaccinia quimerico sintetico.

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Construction of Recombinant Vaccinia Viruses Using Leporipoxvirus-Catalyzed Recombination and Reactivation ofOrthopoxvirus DNA;YAO, X.-D. et al.;《Methods in Molecular Biology》;20041231;第269卷;Materials; Methods *
High-Frequency Genetic Recombination and Reactivation ofOrthopoxviruses from DNA Fragments Transfected into Leporipoxvirus-Infected Cells;YAO, X.-D. et al.;《Journal of Virology》;20031231;第77卷(第13期);Abstract; page 7281, column 2; Materials and Methods *
Incompletely base-paired flip-flop terminal loops link the two DNA strands of the vaccinia virus genome into one uninterrupted polynucleotide chain;BARO UDY B M ET AL;CELL;第28卷(第2期);全文 *
Vaccinia virus DNA replication: Two hundred base pairs of telomeric sequence confer optimal replication efficiency on minichromosome templates;Du Shan ET AL;Proc. Natl. Acad. Sci;第93卷;全文 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112543806B (zh) * 2018-05-02 2025-06-06 戴维·埃文斯 合成嵌合痘苗病毒

Also Published As

Publication number Publication date
TW201819400A (zh) 2018-06-01
JP2019535311A (ja) 2019-12-12
ZA201902868B (en) 2022-12-21
US20180251736A1 (en) 2018-09-06
AU2017353868C1 (en) 2024-06-06
EP3535389A1 (en) 2019-09-11
IL266399B1 (en) 2025-05-01
IL266399B2 (en) 2025-09-01
JP2022164900A (ja) 2022-10-27
US20230002741A1 (en) 2023-01-05
CN110431228A (zh) 2019-11-08
WO2018085582A1 (en) 2018-05-11
SG11201903893PA (en) 2019-05-30
JP2024107257A (ja) 2024-08-08
AU2024200997A1 (en) 2024-03-07
IL319942A (en) 2025-05-01
TW202528334A (zh) 2025-07-16
CA3042694A1 (en) 2018-05-11
EP3535389A4 (en) 2020-06-03
MX2019005102A (es) 2019-10-30
AU2017353868A1 (en) 2019-05-16
NZ752893A (en) 2025-10-31
TWI887191B (zh) 2025-06-21
ZA202403393B (en) 2025-08-27
US12365879B2 (en) 2025-07-22
AU2017353868B2 (en) 2024-02-29
IL266399A (en) 2019-06-30
US11345896B2 (en) 2022-05-31
BR112019008781A2 (pt) 2019-07-16
ZA202204981B (en) 2024-09-25

Similar Documents

Publication Publication Date Title
CN110431228B (zh) 合成嵌合痘病毒
JP2024051112A (ja) 合成キメラワクシニアウイルス
EP4110386A1 (en) Recombinant poxvirus based vaccine against sars-cov-2 virus
US20210236619A1 (en) Stem cells comprising synthetic chimeric vaccinia virus and methods of using them
HK40014109B (zh) 合成嵌合痘病毒
HK40014109A (en) Synthetic chimeric poxviruses
WO2023168286A1 (en) Recombinant poxvirus based vaccine against the omicron strain of sars-cov-2 virus and variants thereof
Holley Mechanistic Constraints on the Formation of Virion Morphotypes in Vaccinia Virus
Ríos et al. INVESTIGATION OF POXVIRUS HOST-RANGE AND GENE EXPRESSION IN MAMMALIAN CELLS.

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40014109

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment
TG01 Patent term adjustment